Variables | TTP | OS | |||||||
---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | ||||||
HR (95% Cl) | P | HR (95% Cl) | P | HR (95% Cl) | P | HR (95% Cl) | P | ||
Gender (Male vs. Female) | 0.956(0.634–1.441) | 0.830 | 0.821(0.507–1.328) | 0.421 | |||||
Age (< 60 vs. ≥ 60) | 0.905(0.595–1.377) | 0.642 | 1.583(0.979–2.559) | 0.061 | |||||
Smoking status (No vs. Yes) | 1.333(0.820–2.165) | 0.246 | 1.472(0.846–2.560) | 0.171 | |||||
ECOG PS (0–1 vs. 2) | 2.694(0.974–7.455) | 0.056 | 1.429(0.445–4.590) | 0.549 | |||||
Clinical stage (IIIB/C vs. IV) | 1.188(0.682–2.069) | 0.543 | 3.135(1.417–6.935) | 0.005 | 2.640(1.061–6.564) | 0.037 | |||
Brain metastases (No vs. Yes) | 1.892(1.200–2.984) | 0.006 | 2.065(1.305–3.269) | 0.002 | 1.950(1.162–3.270) | 0.011 | 2.136(1.207–3.781) | 0.009 | |
Bone metastases (No vs. Yes) | 1.100(0.731–1.654) | 0.648 | 1.796(1.106–2.918) | 0.018 | 1.517(0.892–2.580) | 0.124 | |||
Liver metastases (No vs. Yes) | 1.256(0.665–2.372) | 0.482 | 2.171(1.096–4.301) | 0.026 | 1.365(0.666–2.798) | 0.396 | |||
EGFR 21 L858R mutation (No vs. Yes) | 0.903(0.734–1.111) | 0.333 | 0.774 (0.610–0.982) | 0.035 | 2.221(1.314–3.752) | 0.003 | |||
TP53 mutation (Exon8 vs. Other Exons) | 0.835(0.490–1.424) | 0.509 | 0.795 (0.431–1.465) | 0.462 | |||||
T790M status at progression (NA vs. Positive) | 0.673(0.445–1.018) | 0.061 | 0.378(0.227–0.631) | P < 0.001 | 0.294(0.169–0.510) | P < 0.001 | |||
Treatment (T vs. TC) | 0.465(0.297–0.728) | 0.001 | 0.438(0.279–0.687) | P < 0.001 | 0.623 (0.364–1.065) | 0.084 |